Combination Antibiotic Treatment With Linezolid for Staphylococcus Aureus Bacteraemia: a Randomised Controlled Trial
Status: Recruiting
Location: See all (12) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The aim of the study is to assess whether targeting virulence factors by administering linezolid in addition to standard antibiotic treatment improves outcomes in patients with Staphylococcus aureus bacteraemia.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Staphylococcus aureus (S. aureus) grown from at least one blood culture
• Hospitalised at a participating centre
• ≥18 years old
• Written informed consent or fulfilling criteria for an emergency exception from informed consent requirements
Locations
Other Locations
Switzerland
Kantonsspital Aarau (KSA)
NOT_YET_RECRUITING
Aarau
St. Claraspital
NOT_YET_RECRUITING
Basel
University Hospital Basel (USB)
RECRUITING
Basel
Inselspital Bern
NOT_YET_RECRUITING
Bern
Hôpital du Jura
NOT_YET_RECRUITING
Delémont
Hôpitaux universitaires de Genève (HUG)
NOT_YET_RECRUITING
Geneva
Centre hospitalier universitaire vaudois (CHUV)
NOT_YET_RECRUITING
Lausanne
Ente Ospedaliero Cantonale (EOC)
NOT_YET_RECRUITING
Lugano
HOCH Health Ostschweiz, Kantonsspital St.Gallen
NOT_YET_RECRUITING
Sankt Gallen
Kantonsspital Winterthur (KSW)
NOT_YET_RECRUITING
Winterthur
Stadtspital Zürich Triemli
NOT_YET_RECRUITING
Zurich
Universitätsspital Zürich (USZ)
NOT_YET_RECRUITING
Zurich
Contact Information
Primary
Richard Kühl, PD Dr. med.
richardalexander.kuehl@usb.ch
+41 61 328 66 61
Backup
Natalie Rose, PhD
natalie.rose@usb.ch
+41 61 328 35 54
Time Frame
Start Date: 2025-10-06
Estimated Completion Date: 2028-10
Participants
Target number of participants: 606
Treatments
Experimental: Linezolid
600mg twice a day for 5 days (in addition to the standard antibiotic treatment)
Placebo_comparator: Placebo
oral placebo tablets twice a day for 5 days (in addition to the standard antibiotic treatment)
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Basel, Switzerland
Collaborators: Swiss National Science Foundation